Karen Gagnon, NP
Nurse Practitioner · Dearborn, MINPI 1417223520
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.4% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Among nurse practitioner clinicians in MI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $30.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$2K
- AbbVie$1K
- Johnson & Johnson$867
- Neurocrine Biosciences, Inc.$794
- Axsome Therapeutics, Inc.$668
- plus $3K from 17 others
What the payments were for
- Food & beverage$9,61099%
- Education$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 54 | $1,708 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,681 |
| AbbVie | 46 | $1,194 |
| Johnson & Johnson | 14 | $867 |
| Neurocrine Biosciences, Inc. | 15 | $794 |
| Axsome Therapeutics, Inc. | 18 | $668 |
| Alkermes, Inc. | 15 | $544 |
| Lundbeck LLC | 20 | $385 |
| Supernus Pharmaceuticals, Inc. | 4 | $287 |
| Sunovion Pharmaceuticals Inc. | 21 | $285 |
| Vanda Pharmaceuticals Inc. | 8 | $268 |
| Teva Pharmaceuticals USA, Inc. | 6 | $239 |
| Idorsia Pharmaceuticals US Inc | 7 | $205 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $156 |
| Ironshore Pharmaceuticals Inc. | 6 | $126 |
| Corium, LLC | 3 | $56 |
| Tris Pharma Inc | 3 | $52 |
| E.r. Squibb & Sons, L.L.C. | 2 | $50 |
| Almatica Pharma LLC | 2 | $43 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $17 |
| Indivior Inc. | 1 | $14 |
| Noven Therapeutics, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$843
- REXULTI$693
- INGREZZA$612
- INVEGA SUSTENNA$504
- LYBALVI$488
- Auvelity$487
- VRAYLAR$374
- QELBREE$250
- QUVIVIQ$125
- INVEGA TRINZA$125
- Fanapt$125
- ABILIFY MAINTENA$121
- ABILIFY ASIMTUFII$121
- UZEDY$120
How this compares
$9,669 in reported general payments places this provider in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 121 | $199,971 |
| Invega SustennaPaliperidone Palmitate | 47 | $138,037 |
| CaplytaLumateperone Tosylate | 80 | $131,374 |
| VraylarCariprazine Hcl | 56 | $83,477 |
| FanaptIloperidone | 21 | $44,040 |
| Abilify MaintenaAripiprazole | 13 | $37,344 |
| NuedextaDextromethorphan Hbr/Quinidine | 34 | $35,605 |
| Paliperidone ErPaliperidone | 178 | $27,393 |
| Chlorpromazine Hcl | 34 | $21,706 |
| Quetiapine Fumarate | 701 | $15,620 |
| Lurasidone Hcl | 120 | $13,984 |
| Naltrexone Hcl | 111 | $8,904 |
| VyvanseLisdexamfetamine Dimesylate | 25 | $8,878 |
| Olanzapine | 453 | $8,071 |
| Trazodone Hcl | 450 | $7,757 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti, Abilify Maintena | $1,681 | $237,315134 claims |
| Johnson & JohnsonInvega Sustenna | $867 | $138,03747 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,708 | $131,37480 claims |
| AbbVieVraylar | $1,194 | $83,47756 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $268 | $44,04021 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $21 | $35,60534 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse, Trintellix | $156 | $15,86636 claims |
| Almatica Pharma LLCSertraline Hcl | $43 | $1,640257 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,351 nurse practitioner providers in Michigan.
Other nurse practitioner in Dearborn
- Abubakir BabanDearborn$143K
- Davida KrugerDetroit$739K
- Kari HillSpring Lake$426K
- Kyle FarrPlymouth$243K
- Linda SpencerTroy$217K
- Ellen DillardDetroit$168K
- Golbon AghamohammadiDetroit$157K
- Lisa Astalos ChismWoodhaven$103K
- Martha GoetzPetoskey$101K
- Debra DegraffGrand Rapids$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.